Cost of disorders of the brain in Europe 2010.
By A. Gustavsson, Mikael Svensson, F. Jacobi, C. Allgulander, J. Alonso, E. Beghi, R. Dodel, M. Ekman, C. Faravelli, Laura Fratiglioni and 33 more. European Neuropsychopharmacology, 2011
1,505 citations recorded by the source corpus.
Subfields: Epidemiology, Medical Terminology, Neurology
View Paper: https://www.semanticscholar.org/paper/2d400c229e070b861c78cd316fefaac8971cd1bb
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Neurology
Citations in the corpus
- Psychedelics Promote Structural and Functional Neural Plasticity (2018, background): “…capable of promoting structural and functional neural plasticity in the PFC (Castrén and Antila, 2017; Cramer et al., 2011; Duman, 2002; Hayley and Litteljohn, 2013; Kolb and Muhammad, 2014; Krystal et al., 2009; Mathew et al., 2008), providing a general solution to treating all of these related…”
- Glutamate and dopamine in schizophrenia: an update for the 21st century (2015, background): “In addition to the high morbidity and mortality rate associated with schizophrenia, the health and social care costs for the illness are substantial: total costs of care for individuals with schizophrenia in the UK amount to 16.7 billion EURO per annum, while for Europe the figure is 93.9 billion EU”
- Inflammation in Fear- and Anxiety-Based Disorders: PTSD, GAD, and Beyond (2017, background): “Together, fear- and anxiety-based psychiatric disorders are at the same time the most prevalent (Kessler et al, 2005) and the most costly of mental health disorders (Gustavsson et al, 2011).”
- Hybrid carbon based nanomaterials for electrochemical detection of biomolecules (2017, background): “It has been estimated that currently up to 27 % of the adult population in Europe are affected by mental and neurological disorders [1].”